相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
Yosuke Ando et al.
INVESTIGATIONAL NEW DRUGS (2020)
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
Federico Nichetti et al.
CANCERS (2020)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance
Marcus A. Couey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immunotherapy-induced acute pulmonary thromboembolism: A case report
Waseem Abbas et al.
SOUTH ASIAN JOURNAL OF CANCER (2019)
Arterial thrombosis and anti-PD-1 blockade
Celine Boutros et al.
EUROPEAN JOURNAL OF CANCER (2018)
Frequency, risk actors, and impact on mortality of arterial thromboembolism in patients with cancer
Ella Grilz et al.
HAEMATOLOGICA (2018)
Pembrolizumab-induced acute thrombosis: A case report
Kei Kunimasa et al.
MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Frequency, risk actors, and impact on mortality of arterial thromboembolism in patients with cancer
Ella Grilz et al.
HAEMATOLOGICA (2018)
Risk of Arterial Thromboembolism in Patients With Cancer
Babak B. Navi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Cihan Ay et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer A population-based cohort study
Alexander T. Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients
Matthias Totzeck et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab
Aparna Madhukeshwar Hegde et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hypercoagulabilty, venous thromboembolism, and death in patients with cancer A Multi-State Model
Florian Posch et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Platelets at the interface of thrombosis, inflammation, and cancer
Aime T. Franco et al.
BLOOD (2015)
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
S. Kaatz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice
Clement Cochain et al.
PLOS ONE (2014)
Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS)
Oliver Königsbrügge et al.
THROMBOSIS RESEARCH (2014)
Epidemiology of cancer-associated venous thrombosis
Jasmijn F. Timp et al.
BLOOD (2013)
Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study
Boris Dickmann et al.
HAEMATOLOGICA (2013)
Thrombosis as an intravascular effector of innate immunity
Bernd Engelmann et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
Sonia Seng et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis
Tracy Proverbs-Singh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation
De-xiu Bu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Arterial thrombosis in ambulatory cancer patients treated with chemotherapy
Marcello Di Nisio et al.
THROMBOSIS RESEARCH (2011)
Prediction of venous thromboembolism in cancer patients
Cihan Ay et al.
BLOOD (2010)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Inflammation and thrombosis
CT Esmon
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
分享论文
